Journal
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 45, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/emm.2013.77
Keywords
therapeutics; ulcerative colitis; WKYMVm
Funding
- National Research Foundation of Korea (NRF)
- Korean government (MEST) [35B-2011-1-E00012, 2013 041811, 2012R1A2A2A01007751]
- Next generation of BioGreen 21 project from Rural Development Administration, Republic of Korea [PJ008196]
- National Research Foundation of Korea [35B-2011-1-E00012, 2012R1A2A2A01007751] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
In this study, we examined the therapeutic effects of an immune-stimulating peptide, WKYMVm, in ulcerative colitis. The administration of WKYMVm to dextran sodium sulfate (DSS)-treated mice reversed decreases in body weight, bleeding score and stool score in addition to reversing DSS-induced mucosa destruction and shortened colon. The WKYMVm-induced therapeutic effect against ulcerative colitis was strongly inhibited by a formyl peptide receptor (FPR) 2 antagonist, WRWWWW, indicating the crucial role of FPR2 in this effect. Mechanistically, WKYMVm effectively decreases intestinal permeability by stimulating colon epithelial cell proliferation. WKYMVm also strongly decreases interleukin-23 and transforming growth factor-beta production in the colon of DSS-treated mice. We suggest that the potent immune-modulating peptide WKYMVm and its receptor FPR2 may be useful in the development of efficient therapeutic agents against chronic intestinal inflammatory diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
